The primary objective of the study is to evaluate real-world effectiveness of treatment with Repatha® in combination with SOC, compared with SOC alone, on the risk for cardiovascular (CV) death, myocardial infarction (MI), stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in participants with established atherosclerotic CV disease (ASCVD) treated with SOC, according to local clinical practice.
Adult participants ≥ 18 years of age.
Participants or participant's legally authorized representative has provided informed consent to participate in this study.
Prescribed Repatha® in addition to an existing SOC treatment according to local guidelines and approved label.
Already received SOC treatment prior to enrollment.
Stroke within past 1 month.
Known hemorrhagic stroke at any time.
Stroke due to thromboembolic event.
Any prior use of Repatha® or other proprotein convertase subtilisin/kexin type 9 inhibition treatments within past 6 months prior to enrollment.
Amgen
Lead sponsor